[ad_1]
Jakarta, CNBC Indonesia – PT Bio Farma (Persero) said that until now the results of the phase three clinical trial for the Covid-19 vaccine, CoronaVac from Sinovac were still ongoing. Therefore, the level of efficacy of this vaccine is not yet known.
Bio Farma Corporate Secretary Bambang Heriyanto said the interim report on the results of the clinical trial is expected to be published in January 2021.
“As of now, the phase 3 clinical trial is still ongoing, and the interim report is estimated to be available in January,” Bambang told CNBC Indonesia on Tuesday (8/12/2020).
It revealed that the results of the clinical trial team report from the Padjadjaran University Faculty of Medicine would be the basis for the Food and Drug Supervision Agency (BPOM) to approve its emergency use.
“Clinical trial data from the Unpad College of Medicine clinical trial team will then be sent directly to BPOM for evaluation for the approval process for emergency use,” he explained.
Previously, the Sinovac corona vaccine was claimed to have a 97% efficacy rate against Covid-19.
“Our clinical trial team found that preliminary data showed an efficacy of up to 97%,” said Iwan Setiawan, spokesperson for Bio Farma, as quoted by Reuters on Tuesday (8/12/2020).
However, Iwan did not specify whether this data came from an end-stage clinical trial, but later revealed that Bio Farma is still collecting data on the efficacy of the vaccine from the ongoing phase three clinical trial.
Previously, Sinovac revealed that its CoronaVac vaccine has a 97% efficacy rate against Covid-19 infection in healthy adults who received lower doses in phase 1 and phase 2 clinical trials.
A Sinovac spokesperson said that as of today, the company has not received an efficacy reading of its Phase 3 clinical trials. The Brazilian Butantan Institute is expected to release data on its end-stage clinical trials in Brazil on 15 May. December 2020.
[Gambas:Video CNBC]
(dru)
